Alarelin/CAS 79561-22-1/Alarelin Acetate 

$35,000.00

Alarelin (usually administered as alarelin acetate) is a synthetic Gonadotropin-Releasing Hormone (GnRH) agonist.

Category:
  • Alarelin API (CAS 79561-22-1) is a high-purity, pharmaceutical-grade GnRH Agonist synthesized via advanced solid-phase peptide synthesis, fully complying with USP and EP quality standards. Its molecular structure mimics natural gonadotropin-releasing hormone, enabling it to selectively bind to pituitary GnRH receptors, initially stimulating and then downregulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. Produced with strict control over peptide purity (≥99%) and biological activity, each batch undergoes rigorous validation, making it a reliable raw material for hormone-regulating drug formulation.
  • This potent peptide agonist stands out for its long-acting and targeted hormone-modulating effects, ideal for treating hormone-dependent conditions such as endometriosis, uterine fibroids, and precocious puberty. Unlike non-specific hormone therapies, it offers precise control over reproductive hormone levels, minimizing systemic side effects. Its stable chemical structure supports formulation into injectable solutions and sustained-release preparations, catering to diverse clinical needs for long-term treatment.
  • Alarelin API (CAS 79561-22-1) caters to professional users: pharmaceutical manufacturers developing endocrine medications, biotech firms advancing reproductive therapy drugs, and research institutions studying hormone regulation. Its proven clinical efficacy, pharmaceutical-grade purity, and targeted mechanism make it a top choice for buyers prioritizing reliability and therapeutic precision. Whether for large-scale commercial production or preclinical research, this GnRH Agonist meets the stringent demands of the global endocrine pharmaceutical sector.

Reviews

There are no reviews yet.

Be the first to review “Alarelin/CAS 79561-22-1/Alarelin Acetate ”

Your email address will not be published. Required fields are marked *